Detalhe da pesquisa
1.
Genetic basis and molecular profiling in myeloproliferative neoplasms.
Blood
; 141(16): 1909-1921, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36347013
2.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Blood
; 141(8): 917-929, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356299
3.
Evaluation of the ATM L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms.
Haematologica
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654656
4.
Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.
Blood
; 137(3): 387-391, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32814349
5.
Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Blood
; 137(14): 1920-1931, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33202418
6.
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Am J Hematol
; 98(5): 770-783, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814396
7.
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
Am J Hematol
; 97(4): 390-400, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015307
8.
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.
Blood
; 133(25): 2669-2681, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30902807
9.
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.
Blood
; 134(2): 199-210, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31064751
10.
CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.
Blood
; 133(15): 1677-1690, 2019 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30635286
11.
Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo.
Am J Hematol
; 96(6): 698-707, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761144
12.
5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines.
Arch Pharm (Weinheim)
; 354(4): e2000342, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33241558
13.
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
Blood
; 132(7): 694-706, 2018 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29907599
14.
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Haematologica
; 105(2): 435-447, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31123029
15.
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Blood
; 129(6): 667-679, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028029
16.
International external quality assurance of JAK2 V617F quantification.
Ann Hematol
; 98(5): 1111-1118, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30535576
17.
Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.
Blood
; 128(10): 1418-23, 2016 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27389715
18.
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Blood
; 127(10): 1317-24, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26608331
19.
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Blood
; 127(10): 1325-35, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26668133
20.
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Blood
; 127(3): 325-32, 2016 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26423830